Study results support ‘obesity paradox’ in GI cancers treated with immunotherapy

CHICAGO — Obesity has been associated with multiple gastrointestinal cancers, but patients with these malignancies and obesity who have been treated with immunotherapy appear to survive significantly longer than those with normal BMI.Data from a retrospective analysis, presented at ASCO Annual Meeting, reveal an “obesity paradox,” where patients with hepatocellular carcinoma or